Group One Trading’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-35,400
| Closed | -$45K | – | 8486 |
|
|
2023
Q3 | $45K | Buy |
35,400
+31,900
| +911% | +$27.9K | ﹤0.01% | 5199 |
|
|
2023
Q2 | $1.14K | Sell |
3,500
-100
| -3% | -$36 | ﹤0.01% | 7234 |
|
|
2023
Q1 | $1.55K | Sell |
3,600
-1,500
| -29% | -$791 | ﹤0.01% | 6673 |
|
|
2022
Q4 | $2.7K | Sell |
5,100
-100
| -2% | -$63 | ﹤0.01% | 6553 |
|
|
2022
Q3 | $4K | Sell |
5,200
-4,700
| -47% | -$5.33K | ﹤0.01% | 6977 |
|
|
2022
Q2 | $11K | Sell |
9,900
-7,800
| -44% | -$9.93K | ﹤0.01% | 6729 |
|
|
2022
Q1 | $36K | Sell |
17,700
-68,400
| -79% | -$163K | ﹤0.01% | 6362 |
|
|
2021
Q4 | $248K | Sell |
86,100
-23,900
| -22% | -$88.4K | ﹤0.01% | 4877 |
|
|
2021
Q3 | $466K | Sell |
110,000
-85,400
| -44% | -$381K | ﹤0.01% | 4275 |
|
|
2021
Q2 | $1.03M | Sell |
195,400
-19,900
| -9% | -$95.7K | ﹤0.01% | 3379 |
|
|
2021
Q1 | $1M | Buy |
215,300
+100,000
| +87% | +$453K | ﹤0.01% | 3228 |
|
|
2020
Q4 | $380K | Sell |
115,300
-10,900
| -9% | -$41.4K | ﹤0.01% | 3521 |
|
|
2020
Q3 | $418K | Sell |
126,200
-358,300
| -74% | -$1.32M | ﹤0.01% | 3002 |
|
|
2020
Q2 | $1.63M | Buy |
484,500
+408,900
| +541% | +$1.93M | 0.01% | 1617 |
|
|
2020
Q1 | $290K | Sell |
75,600
-55,700
| -42% | -$259K | ﹤0.01% | 2458 |
|
|
2019
Q4 | $793K | Buy |
131,300
+41,700
| +47% | +$285K | 0.01% | 2081 |
|
|
2019
Q3 | $677K | Buy |
89,600
+49,500
| +123% | +$558K | 0.01% | 2080 |
|
|
2019
Q2 | $543K | Buy |
40,100
+4,700
| +13% | +$54.3K | ﹤0.01% | 2065 |
|
|
2019
Q1 | $192K | Sell |
35,400
-3,000
| -8% | -$14.6K | ﹤0.01% | 2741 |
|
|
2018
Q4 | $114K | Buy |
38,400
+300
| +0.8% | +$1.64K | ﹤0.01% | 3098 |
|
|
2018
Q3 | $311K | Sell |
38,100
-5,400
| -12% | -$41.4K | ﹤0.01% | 2678 |
|
|
2018
Q2 | $424K | Buy |
43,500
+17,900
| +70% | +$183K | ﹤0.01% | 2430 |
|
|
2018
Q1 | $222K | Sell |
25,600
-50,000
| -66% | -$539K | ﹤0.01% | 2718 |
|
|
2017
Q4 | $947K | Sell |
75,600
-124,900
| -62% | -$1.43M | 0.01% | 1749 |
|
|
2017
Q3 | $1.68M | Buy |
200,500
+130,800
| +188% | +$1.38M | 0.02% | 1177 |
|
|
2017
Q2 | $1.18M | Sell |
69,700
-38,100
| -35% | -$758K | 0.01% | 1322 |
|
|
2017
Q1 | $2.17M | Buy |
107,800
+37,900
| +54% | +$753K | 0.03% | 816 |
|
|
2016
Q4 | $1.09M | Buy |
69,900
+61,500
| +732% | +$828K | 0.01% | 1266 |
|
|
2016
Q3 | $110K | Buy |
+8,400
| New | +$79.8K | ﹤0.01% | 2870 |
|
Group One Trading's ZYNE Position: Q3 2023 in Review
Group One Trading sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q3 2023, closing a stake of 4,559 shares — an estimated $3.98K sold.
Group One Trading first reported a position in ZYNE in Q2 2017 and held it in 22 quarters. The position peaked at $1.51M in Q2 2019. 43 funds tracked by Wall St. Rank hold ZYNE as of Q3 2023.
- Group One Trading reported no remaining Zynerba Pharmaceuticals, Inc position as of Q3 2023 after selling out during the quarter.
- Group One Trading sold 4,559 Zynerba Pharmaceuticals, Inc shares in Q3 2023, an estimated $3.98K.
- Group One Trading first reported a position in Zynerba Pharmaceuticals, Inc in Q2 2017 and held it in 22 quarters.
- Group One Trading's Zynerba Pharmaceuticals, Inc position peaked at $1.51M in Q2 2019.
- 43 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q3 2023.
Based on Group One Trading's 13F filing for Q3 2023, filed 9 Nov 2023.